A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

NCT00140049 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

238

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open Angle
Ocular Hypertension

Interventions

DRUG: Xalacom
DRUG: Cosopt

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.